Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial
Background: In the phase 3b C-OPTIMISE study (ClinicalTrials.gov, NCT02505542), approximately 80% of patients with early active axial spondyloarthritis (axSpA) remained flare-free from week (W)48 to W96 with full-dose and reduced-dose certolizumab pegol (CZP) after gaining sustained remission (Axial...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2026-06-01
|
| Col·lecció: | EULAR Rheumatology Open |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S3050708126000820 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|